Known targets — ChEMBL curated mechanism
ABL1ACEACHEACVR1ADRA1AADRA1BADRA1DADRA2AADRA2BADRA2CADRB1ADRB2ADRB3AGTR1ALKAVPR1AAVPR2BCHEBCRCA2CACNA1ACACNA1BCACNA1CCACNA1DCACNA1ECACNA1FCACNA1GCACNA1HCACNA1ICACNA1SCACNA2D1CACNA2D2CACNA2D3CACNA2D4CACNB1CACNB2CACNB3CACNB4CACNG1CACNG2CACNG3CACNG4CACNG5CACNG6CACNG7CACNG8CALCRLCASRCCR5CDK4CDK6CFBCHRM1CHRM2CHRM3CHRM4CHRM5CHRNA1CHRNA3CHRNA7CHRNB1CHRNB4CHRNDCHRNECHRNGCOXFA4COXFA4L2CRBNCSF1RCUL4ACYP19A1DDB1DPP4DRD1DRD2DRD3DRD4EDNRAEGFREML4ERBB2ERBB4ESR1ESR2FGFR1FGFR3FLT1FLT3FLT4GAAGABRA1GABRA2GABRA3GABRA4GABRA5GABRA6GABRB1GABRB2GABRB3GABRDGABREGABRG1GABRG2GABRG3GABRPGABRQGHSRGLAGNRHRGPD2GRIN1GRIN2AGRIN2BGRIN2CGRIN2DGRIN3AGRIN3BGSTP1HCN4HCRTR1HCRTR2HDAC1HDAC10HDAC11HDAC2HDAC3HDAC4HDAC5HDAC6HDAC7HDAC8HDAC9HRH1HRH2HRH3HSD11B1HSP90AA1HSP90AB1HTR1AHTR1BHTR1DHTR1EHTR1FHTR2AHTR2BHTR2CHTR3AHTR3BHTR3CHTR3DHTR3EHTR4HTR5AHTR6HTR7IMPDH1IMPDH2ITGA2BITGB3ITKJAK1JAK2KCNA1KCNA10KCNA2KCNA3KCNA4KCNA5KCNA6KCNA7KCNB1KCNB2KCNC1KCNC2KCNC3KCNC4KCND1KCND2KCND3KCNF1KCNG1KCNG2KCNG3KCNG4KCNH1KCNH2KCNH3KCNH4KCNH5KCNH6KCNH7KCNH8KCNJ2KCNJ3KCNJ5KCNK3KCNK9KCNQ1KCNQ2KCNQ3KCNQ4KCNQ5KCNS1KCNS2KCNS3KCNV1KCNV2KDRKITKLKB1LCKMMAOAMAOBMAPK14METMMP1MMP13MMP7MMP8MT-ND1MT-ND2MT-ND3MT-ND4MT-ND4LMT-ND5MT-ND6NDUFA1NDUFA10NDUFA11NDUFA12NDUFA13NDUFA2NDUFA3NDUFA5NDUFA6NDUFA7NDUFA8NDUFA9NDUFAB1NDUFAF1NDUFAF2NDUFAF3NDUFAF4NDUFB1NDUFB10NDUFB11NDUFB2NDUFB3NDUFB4NDUFB5NDUFB6NDUFB7NDUFB8NDUFB9NDUFC1NDUFC2NDUFS1NDUFS2NDUFS3NDUFS4NDUFS5NDUFS6NDUFS7NDUFS8NDUFV1NDUFV2NDUFV3NR3C1NS5ANTRK1NTRK2NTRK3ODC1OPRD1OPRK1OPRM1P2RY12PAHPARP1PDE3APDE3BPDE4APDE4BPDE4CPDE4DPDE5APDE7APDE7BPDE8APDE8BPDGFRAPDGFRBPIK3CAPIK3CDPNPPOLA1POLA2POLD1POLD2POLD3POLD4POLEPOLE2POLE3PPARGPRIM1PRIM2PRKCAPRKCBPRKCDPRKCEPRKCGPRKCHPRKCIPRKCQPRKCZPRKD1PRKD3PTGS1PTGS2RBX1RENRETROCK1ROCK2RPE65RRM1RRM2RRM2BS1PR1S1PR2S1PR3S1PR4S1PR5SCN10ASCN11ASCN1ASCN2ASCN3ASCN4ASCN5ASCN7ASCN8ASCN9ASCNN1ASCNN1BSCNN1GSIGMAR1SLC18A2SLC6A1SLC6A2SLC6A3SLC6A4SLC9A3SRCTACR1TOP1TOP2ATOP2BTTRTYMPdacAdacBdacCembAfolAftsIgyrAgyrBmrcAmrcBmrdAparCparEpolrplArplBrplCrplDrplErplFrplIrplJrplKrplLrplMrplNrplOrplPrplQrplRrplSrplTrplUrplVrplWrplXrplYrpmArpmBrpmCrpmDrpmErpmE2rpmFrpmGrpmG1rpmG2rpmG3rpmHrpmIrpmJrpsArpsBrpsCrpsDrpsErpsFrpsGrpsHrpsIrpsJrpsKrpsLrpsMrpsNrpsOrpsPrpsQrpsRrpsSrpsTrpsUykgMykgO
The experimentally established mechanism targets of Hydrochloric Acid. The predicted profile below is derived independently by chemical similarity — agreement is a validation signal, a miss is honest.
Predicted protein targets (top 12)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | CACNA2D1 known ✓ | P54289 | 1/20 | 0.48 |
| ▸ | CYP2C19 | P33261 | 1/20 | 0.58 |
| ▸ | USP2 | O75604 | 1/20 | 0.48 |
| ▸ | ALDH1A1 | P00352 | 1/20 | 0.48 |
| ▸ | LMNA | P02545 | 1/20 | 0.48 |
| ▸ | CYP1A2 | P05177 | 1/20 | 0.48 |
| ▸ | TSHR | P16473 | 1/20 | 0.48 |
| ▸ | BLM | P54132 | 1/20 | 0.48 |
| ▸ | SMN1; SMN2 | Q16637 | 1/20 | 0.48 |
| ▸ | CPB2 | Q96IY4 | 6/20 | 0.39 |
| ▸ | TBXAS1 | P24557 | 2/20 | 0.37 |
| ▸ | MME | P08473 | 1/20 | 0.34 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL1526434 | 0.98 | CYP2C19 (0.60) | CYP2C19USP2ALDH1A1LMNACYP1A2 | |
| Hydrochloric Acid SCHEMBL20773302 | 0.98 | CYP2C19 (0.54) | CYP2C19USP2ALDH1A1LMNACYP1A2 | |
| SCHEMBL1821191 | 0.95 | CYP2C19 (0.56) | CYP2C19USP2ALDH1A1LMNACYP1A2 | |
| Hydrochloric Acid SCHEMBL21930733 | 0.93 | CYP2C19 (0.48) | CYP2C19USP2ALDH1A1LMNACYP1A2 | |
| SCHEMBL15268430 | 0.90 | — | — | |
| Hydrochloric Acid SCHEMBL5665222 | 0.87 | — | — | |
| Hydrochloric Acid SCHEMBL2745410 | 0.86 | CYP2C19 (0.54) | CYP2C19USP2ALDH1A1LMNACYP1A2 | |
| Hydrochloric Acid SCHEMBL2234516 | 0.85 | CYP2C19 (0.44) | CYP2C19USP2ALDH1A1LMNACYP1A2 | |
| Hydrochloric Acid SCHEMBL2471024 | 0.85 | CYP2C19 (0.44) | CYP2C19USP2ALDH1A1LMNACYP1A2 | |
| SCHEMBL1527341 | 0.85 | — | — |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 21 patents — showing the first 20. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| EP-2116526-B1 | DERIVATES OF SUBSTITUTED TARTARIC AICD AND USAGE FOR PREPARATING BETA SECRETASE INHIBITORS | INST PHARMACOLOGY & TOXICOLOGY ACADEMY MILITARY MEDICAL SCIENCES PLA CHINA (CN) | 2018-04-18 | — | — | EP | disclosed |
| EP-2250998-B1 | SKIN WHITENING AGENT AND EXTERNAL PREPARATION FOR THE SKIN | SHISEIDO CO LTD (JP) | 2016-04-13 | — | — | EP | disclosed |
| EP-2250999-B1 | SKIN WHITENING AGENT AND EXTERNAL PREPARATION FOR THE SKIN | SHISEIDO CO LTD (JP) | 2016-04-13 | — | — | EP | disclosed |
| EP-2707372-A2 | SPIRO-OXINDOLE MDM2 ANTAGONISTS | The Regents Of The University Of Michigan (US) | 2014-03-19 | — | — | EP | disclosed |
| WO-2013177349-A2 | QUINAZOLINEDIONES AS TANKYRASE INHIBITORS | GLAXOSMITHKLINE LLC (US) | 2013-11-28 | — | — | WO | disclosed |
| US-8563552-B2 | Whitening agent and skin external preparation | SHISEIDO COMPANY LTD. (JP) | 2013-10-22 | — | — | US | disclosed |
| US-8426435-B2 | Method for inhibiting melanin production and whitening skin with pyrimidlypyrazole compounds or pharmaceutically acceptable salts thereof | SHISEIDO COMPANY LTD. (JP) | 2013-04-23 | — | — | US | disclosed |
| US-20130045173-A1 | Method For Inhibiting Melanin Production And Whitening Skin With Pyrimidlypyrazole Compounds Or Pharmaceutically Acceptable Salts Thereof | SHISEDIO COMPANY LTD. (JP) | 2013-02-21 | — | — | US | disclosed |
| US-8324234-B2 | Method for inhibiting melanin production and whitening skin with pyrimidylpyrazole compounds or pharmaceutically acceptable salts thereof | SHISEIDO COMPANY LTD. (JP) | 2012-12-04 | — | — | US | disclosed |
| WO-2012155066-A2 | SPIRO-OXINDOLE MDM2 ANTAGONISTS | WANG SHAOMENG (US) | 2012-11-15 | — | — | WO | disclosed |
| US-8211412-B2 | Method for skin whitening | SHISEIDO COMPANY LTD. (JP) | 2012-07-03 | — | — | US | disclosed |
| US-20120134944-A1 | Whitening Agent And Skin External Preparation | SHISEIDO COMPANY LTD. (JP) | 2012-05-31 | — | — | US | disclosed |
| US-20110003838-A1 | Whitening Agent And Skin External Preparation | SHISEIDO COMPANY LTD. (JP) | 2011-01-06 | — | — | US | disclosed |
| US-20110003817-A1 | Whitening Agent And Skin External Preparation | SHISEIDO COMPANY LTD. (JP) | 2011-01-06 | — | — | US | disclosed |
| US-20100331345-A1 | DERIVATIVES OF SUBSTITUTED TARTARIC ACID AND USAGE FOR PREPARING BETA-SECRETASE INHIBITORS | INSTITUTE OF PHARMACOLOGY AND TOXICOLOGY ACADEMY OF MILITARY MEDICAL SCIENCES P.L.A. CHINA (CN) | 2010-12-30 | — | — | US | disclosed |
| US-20100324096-A1 | Whitening Agent And Skin External Preparation | SHISEIDO COMPANY LTD. (JP) | 2010-12-23 | — | — | US | disclosed |
| EP-2250998-A1 | SKIN WHITENING AGENT AND EXTERNAL PREPARATION FOR THE SKIN | Shiseido Company, Ltd. (JP) | 2010-11-17 | — | — | EP | disclosed |
| EP-2251000-A1 | SKIN WHITENING AGENT AND EXTERNAL PREPARATION FOR THE SKIN | Shiseido Company, Ltd. (JP) | 2010-11-17 | — | — | EP | disclosed |
| WO-2009145378-A1 | GD COMPLEX COMPRISING DTPA-BIS-AMIDE LIGAND AND METHOD FOR PREPARING THE SAME | KYUNGPOOK NATIONAL UNIVERSITY INDUSTRY-ACADEMIC COOPERATION FOUNDATION (KR) | 2009-12-03 | — | — | WO | disclosed |
| EP-2116526-A1 | DERIVATES OF SUBSTITUTED TARTARIC AICD AND USAGE FOR PREPARATING BETA SECRETASE INHIBITORS | Institute of Pharmacology and Toxicology Academy of Military Medical Sciences P.L.A. China (CN) | 2009-11-11 | — | — | EP | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (6 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20110003838-A1 | Whitening Agent And Skin External Preparation | TYR, MC1R, MCHR1 | CACNA2D1 3459/4885CYP2C19 704/4885USP2 2999/4885 |
| US-20110003817-A1 | Whitening Agent And Skin External Preparation | TYR, MC1R, RTN3 | CACNA2D1 1375/4885CYP2C19 562/4885USP2 2896/4885 |
| US-20100324096-A1 | Whitening Agent And Skin External Preparation | TYR, MC1R, PAH | CACNA2D1 3340/4885CYP2C19 671/4885USP2 3787/4885 |
| US-20120134944-A1 | Whitening Agent And Skin External Preparation | TYR, MC1R, MCHR1 | CACNA2D1 2800/4885CYP2C19 584/4885USP2 3529/4885 |
| US-20130045173-A1 | Method For Inhibiting Melanin Production And Whitening Skin With Pyrimidlypyrazole Compounds Or Pharmaceutically Acceptable Salts Thereof | TYR, MC1R, TH | CACNA2D1 4179/4885CYP2C19 15/4885USP2 4355/4885 |
| US-20100331345-A1 | DERIVATIVES OF SUBSTITUTED TARTARIC ACID AND USAGE FOR PREPARING BETA-SECRETASE INHIBITORS | BACE1, APP, BACE2 | CACNA2D1 529/4885CYP2C19 791/4885USP2 2264/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.